• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

Section Contents Menu


Record of Telephone Conversation - January 11, 2010 - Prevnar 13

System Info - 116636  SMITH, MICHAEL J  12-Jan-2010 11:23:14  SMITHM


Submission Type: Original Application   Submission ID:  125324/0    Office: OVRR  

Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein)

Wyeth Pharmaceuticals Inc.          

Telecon Date/Time:  11-JAN-2010 11:27 AM               Initiated by FDA?  Yes
Telephone Number:

Communication Categorie(s):


Telecon Summary:
Email: CMC PMC revision regarding the ----(b)(4)--- specification for serotype 1 from ------(b)(4)-----

FDA Participants:   Mike Smith, Julie Vaillancourt and Colleen Sweeney

Non-FDA Participants:    Jack Love and Carmel Devlin

Trans-BLA Group: No

Related STNs:  None

Related PMCs:  None

Telecon Body:


From:                     Smith, Michael (CBER) 
Sent:                      Monday, January 11, 2010 11:27 AM
To:                          'Love Jack'; Devlin Carmel
Cc:                          Vaillancourt, Julienne; Sweeney, Colleen
Subject:                RE: CMC PMC's

Jack and Carmel,

CBER has agreed to your proposed CMC PMC revision regarding the ----(b)(4)----- specification for serotype 1 from -----(b)(4)------.


Mike Smith, Ph.D.
Lieutenant Commander (LCDR), U.S. Public Health Service
Regulatory Project Manager
Division of Vaccines and Related Products Applications
Office of Vaccines Research and Review
Center for Biologics Evaluation and Research
U.S. Food and Drug Administration

Phone:    301-827-9047
BB:         240-839-0823
Fax:        301-827-3532
E-mail:   michael.smith2@fda.hhs.gov

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW.  If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized.  If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

End of email


Contact FDA

(800) 835-4709
(240) 402-8010
Consumer Affairs Branch (CBER)

Division of Communication and Consumer Affairs

Office of Communication, Outreach and Development

Food and Drug Administration

10903 New Hampshire Avenue

Building 71 Room 3103

Silver Spring, MD 20993-0002